Scribe Prices an Upsized $128.7 Million IPO

Company Scribe Therapeutics Event Type Initial Public Offering (Upsized Pricing) Platform Compact CRISPR-Based Epigenetic Editing (LNP-Delivered) Indication Cardiometabolic Disease (Lead Program: PCSK9 Silencing) Summary Scribe Therapeutics priced an upsized initial public offering of 8.58 million shares at $15, raising $128.7 million gross before expenses and…